| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 93.8B | +5% |
| Gross Profit | 36.4B | - |
| Cost Of Revenue | 57.4B | +5% |
| Operating Income | 3.4B | -9% |
| Operating Expenses | - | - |
| Net Income | 2B | -10% |
| Amortization | 509MM | - |
| Interest Expense | 690MM | -0% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
CVS Health (CVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CVS Health® (NYSE: CVS) today announced it has invested $19.2 million through Boston Financial to build 85 new affordable housing units in Arvada, Colorado. Made possible through the company's collaboration with Family Tree and BlueLine Development, the investment demonstrates CVS Health's commitment to improving the health of individuals across the country, which begins with providing access to quality, safe, affordable housing, especially in historically underserved communities.
Baum Family Investments (BFI) proudly announces its official debut in the real estate investment landscape. With over fifteen years of expertise in triple net leased investments and the backing of prominent family offices in Detroit, Miami, and New York, BFI enters the market poised for success.
The average brokerage recommendation (ABR) for CVS Health (CVS) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
In the most recent trading session, CVS Health (CVS) closed at $69.75, indicating a +0.52% shift from the previous trading day.
The agreement may help Alvotech capitalize on a recent policy shift by CVS that has driven major market share declines for AbbVie’s blockbuster drug.
CVS Health (CVS) closed at $69.39 in the latest trading session, marking a +1.15% move from the prior day.
Elevance Health offered skittish investors another signal that health insurers aren’t getting hit with higher-than-expected costs, reporting results that beat Wall Street expectations. Elevance stock rose over 5% early Thursday, on track for its highest close since December 2022. The earnings may help sustain a rally that began Tuesday, when UnitedHealth released results that also came in above analysts’ projections and said healthcare expenses were running at expected rates.
CVS Health (CVS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
The strength of a diversified enterprise, along with robust operational execution, is expected to be reflected in CVS Health's (CVS) first-quarter 2024 results.